Despite its clinical efficacy, ICB is limited by the emergence of MHC-deficient and IFN-unresponsive tumour cell clones that escape recognition and destruction by CD8+ cytolytic T cells4,5. The gene discussed is HLA-C; the disease is neoplasm.